Which b/tsDMARDs are effective in #axSpA? Stratified by extramusculoskeletal manifestations Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/uTxEJqbDBm

Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8

Which b/tsDMARDs are NOT effective in #axSpA? Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/hqfLAYeri3

Key messages in the tx of ax/p-SpA: >csDMARDs only effective in pSpA >consider individualized treatment for bDMARDs and JAKis >Cycling TNFi equally effective to switching @RheumNow #EULAR2026 https://t.co/oeO3BxmYYo

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. https://t.co/mvTRRL7srA

Which b/tsDMARDs are effective in #axSpA? Check out the latest update of the treatment heatmap 🔥 By Astrid van Tubergen At axial and peripheral SpA at a crossroads session #EULAR2026 @RheumNow https://t.co/8mj24lAOTk

What b/ts DMARDs are effective and not effective in axSpA? Prof. Astrid van Tubergen presents this very informative summary slide summarizing treatment in axSpA. @RheumNow #EULAR2026 https://t.co/5udGPB1Hrr

What is the @Official_ASAS recommended instrument for evaluating peripheral disease activity in axial and peripheral spondyloarthritis? 👉 DAPSA44 ✔️Good construct validity ✔️ High discriminatory capacity From the ASAS-Sparadise study #EULAR2026 @RheumNow https://t.co/Jbdvpn95jE

#immune #reset may be ‘asking the earth’ and we may need to consider #immune #dimming ➡️esp if multi drug failure already By Hector Chinoy #WIN #IIM June5 Excellent #CAR-T review should re think of Total immune reset in many #SARD PTS is unlikely EULAR2026 @RheumNow https://t.co/eqKzxzqa0z

Using AI to integrate EHR, SDOH , psychological data - can help finding psychosocial risk factors. Complex cases can be diagnosed using solutions (iceberg health) like this. #EULAR2026 @rheumnow https://t.co/t4keRbpkrx

Not just ticking boxes! Prof. Rudwaleit on the revised 2025 ASAS/SPARTAN criteria for axSpA What’s new? Providing a stem so criteria will be applied only if w/SpA dx, not just imaging MRI:active inflamm + structural lesions Some SpA features omitted @RheumNow #EULAR2026 https://t.co/NCV0EFvjYa

Can we have an effective, comprehensive score for #SLE #arthritis? #SLEDAI has a problem SJC>2 scores dames as ex #SJC=12 Meet #LAMBDA An attempt to improve a true positive #MSK OUTCOME in #lupus Needs validation esp in pts over time #EULAR2026 @RheumNow #POS1072 @eular_org https://t.co/fr0xuVqFnM